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Introduction: We evaluated efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2 
diabetes mellitus (T2DM) inadequately controlled (HbA1c, 7.0–10.5%) on metformin 
monotherapy (≥1500 mg/day for ≥8 weeks). 
Methods: Double-blind, 26-week, multicentre study with ongoing 78-week extension; 621 
participants randomized 1:1:1 to placebo, ertugliflozin 5 or 15 mg/day. Primary endpoint: 
change from baseline in HbA1c at week 26. Secondary efficacy endpoints: change from 
baseline at week 26 in fasting plasma glucose (FPG), body weight, systolic/diastolic blood 
pressure (SBP/DBP); participants with HbA1c <7.0% (53 mmol/mol). Pre-specified adverse 
events (AEs) of special interest and percent change from baseline in bone mineral density 
(BMD) were also assessed at week 26.  
Results: At week 26, the placebo-adjusted least-squares mean change from baseline 
HbA1c (8.1%) was –0.7% and –0.9% for ertugliflozin 5 and 15 mg, respectively (both P < 
0.001), to final means of 7.3% and 7.2%, respectively. The odds of HbA1c <7.0% were 
significantly greater in both ertugliflozin groups vs placebo. Ertugliflozin significantly reduced 
FPG, body weight, SBP and DBP vs placebo. Incidence of genital mycotic infections was 
increased in ertugliflozin groups (females: placebo, 0.9%; ertugliflozin 5 mg, 5.5%; 15 mg, 
6.3% [P = 0.032]; males: 0; 3.1%; 3.2%), as was incidence of urinary tract infections and 
symptomatic hypoglycaemia. Incidence of hypovolaemia AEs was similar across groups. 
Ertugliflozin had no adverse impact on BMD at week 26. 
Conclusions: Ertugliflozin added to metformin in inadequately controlled T2DM improved 
glycaemic control, reduced body weight and BP, but increased genital mycotic infections. 
ClinicalTrials.gov identifier: NCT02033889. 
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1 INTRODUCTION 
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Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the newest class of oral anti-
hyperglycaemic agent (AHA) for the treatment of type 2 diabetes mellitus (T2DM). Several 
SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, and empagliflozin) are currently available 
and have been shown to improve glycaemic control, reduce body weight and blood pressure 
while being generally well tolerated with a low risk of hypoglycaemia, but consistent 
genitourinary adverse events (AEs).1,2 Although there have been no head-to-head 
comparisons of efficacy or safety, the currently available SGLT2 inhibitors differ in terms of 
selectivity, the clinical relevance of which, is presently unknown. Ertugliflozin is a highly 
selective SGLT2 inhibitor with 2000-fold selectivity for SGLT2 over SGLT1 in clinical 
development for the treatment of T2DM.3 Phase II studies have shown that ertugliflozin 
improves glycaemic control and decreases body weight and blood pressure.4,5 Results from 
several phase III studies demonstrate that ertugliflozin, administered over 26 weeks, 
provides clinically meaningful reductions from baseline in glycated haemoglobin (HbA1c), 
body weight and blood pressure.6-8 Ertugliflozin is also being developed as a fixed-dose 
combination (FDC) with sitagliptin and a separate FDC with metformin.  
This phase III study assessed the efficacy and safety of ertugliflozin vs placebo in 
adults with T2DM inadequately controlled on metformin monotherapy. Assessment of bone 
safety has been an area of interest in the evaluation of SGLT2 inhibitors; therefore, bone 
mineral density (BMD) and biomarkers of bone turnover were also evaluated. The study 
population was enriched with women who were ≥3 years postmenopausal to assess BMD 
changes in this population in addition to the overall cohort. 
 
2 MATERIALS AND METHODS 
This 104-week, multicentre, randomized, parallel-group study comprised a 26-week, double-
blind, placebo-controlled treatment period (phase A) followed by an ongoing, 78-week, 
double-blind treatment extension period (phase B). Results from phase A are reported here. 
The final protocol and informed consent documentation were reviewed and approved 
by the Institutional Review Boards or Independent Ethics Committees at each of the 
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investigational centres participating in the study. The study was conducted in compliance 
with the ethical principles of the Declaration of Helsinki and in compliance with all 
International Conference on Harmonisation Good Clinical Practice Guidelines. Written 
informed consent was obtained from all participants.   
 
2.1 Study design 
The study included a screening period (during which, if needed, background diabetes 
medication was adjusted to achieve a minimum 8-week metformin monotherapy stable dose 
[≥1500 mg/day]), followed by a 2-week, single-blind, placebo run-in period prior to 
randomization; a double-blind, placebo-controlled, 26-week treatment period; a double-blind, 
78-week treatment extension period; and a posttreatment telephone contact 14 days after 
the last dose of blinded study medication. Participants were counselled on appropriate 
dietary and lifestyle guidelines for T2DM and asked to maintain these throughout study 
participation. On day 1 (randomization), each participant was assigned (1:1:1) to placebo, 
ertugliflozin 5 mg or ertugliflozin 15 mg using a computer-generated randomization code 
based on the method of random permuted blocks. Randomization was stratified in 4 groups: 
(1) men, (2) pre-menopausal women, (3) women who were perimenopausal or 
postmenopausal for <3 years after last menstrual period (LMP), or with bilateral 
oophorectomy performed <3 years prior to screening, and (4) women who were 
postmenopausal ≥3 years after LMP, or with bilateral oophorectomy performed ≥3 years 
prior to screening. In phase A, participants received glycaemic rescue therapy with open-
label glimepiride if they exceeded the following fasting plasma glucose (FPG) thresholds: 
>15.0 mmol/L (>270 mg/dL) after randomization through week 6, >13.3 mmol/L (>240 
mg/dL) after week 6 through week 12, and >11.1 mmol/L (>200 mg/dL) after week 12 
through week 26. Bone rescue therapy was to be administered to participants with a 
confirmed reduction from baseline in BMD of >7% at any anatomical site together with a T-
score of less than –2.5. Participants receiving glycaemic or bone rescue therapy continued 
to receive ertugliflozin or matching placebo. In phase B, participants randomized to 
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ertugliflozin continued to receive ertugliflozin; those randomized to placebo received blinded 
glimepiride (if not rescued during phase A). 
 
2.2 Participant population 
The study population comprised men and women aged ≥18 years with T2DM (diagnosed in 
accordance with American Diabetes Association guidelines9) inadequately controlled 
(HbA1c, 7.0–10.5% [53–91 mmol/mol] inclusive) on metformin monotherapy (≥1500 mg/day 
for ≥8 weeks) and with BMI 18.0–40.0 kg/m2. 
At screening, participants were receiving either metformin monotherapy ≥1500 
mg/day with HbA1c 7.0–10.5% (53–91 mmol/mol) inclusive, metformin monotherapy <1500 
mg/day with HbA1c 7.5–11.0% (58–97 mmol/mol) inclusive, or dual combination therapy 
comprising metformin and one of the following oral AHAs: sulphonylurea, dipeptidyl 
peptidase-4 inhibitor, meglitinide or alpha-glucosidase inhibitor, with HbA1c 6.5–9.5% (48–
80 mmol/mol) inclusive. Participants who had received dual AHA therapy, metformin 
monotherapy <1500 mg/day or ≥1500 mg/day for <8 weeks were required to adjust their 
background AHA therapy so that, at a second screening visit, they had received metformin 
monotherapy at ≥1500 mg/day for ≥8 weeks. To be eligible for study inclusion, these 
participants underwent a repeat HbA1c measurement for confirmation of HbA1c 7.0–10.5% 
inclusive. Participants were required to be on stable doses of blood pressure and/or lipid-
altering medications for ≥4 weeks prior to randomization.  
Key exclusion criteria included type 1 diabetes mellitus, history of ketoacidosis, 
estimated glomerular filtration rate (eGFR) <55 mL/min/1.73 m2 according to the 4-variable 
modification of diet in renal disease equation10 at screening, <80% compliance (based on pill 
count) with the placebo run-in medication, documented history of osteoporosis or gender-
specific BMD T-score of less than –2.5 at any skeletal site assessed at screening, or any 
illness that could impact BMD assessment. Those who had received prior therapeutic agents 
that could confound BMD assessment or affect bone turnover were also excluded. Use of 
AHAs (other than those approved by the study protocol) and bone active therapeutic agents 
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(e.g. bisphosphonates) was prohibited for the entire duration of the trial. Participants who 
had undergone bariatric surgery were also ineligible. 
 
2.3 Efficacy assessments 
The primary efficacy endpoint was the change from baseline in HbA1c at week 26. Pre-
specified secondary efficacy endpoints were changes from baseline at week 26 in FPG, 
body weight, systolic and diastolic blood pressure (SBP; DBP). Participants with HbA1c 
<7.0% (53 mmol/mol) at week 26 and proportions who received glycaemic rescue therapy 
were also evaluated. Body weight was measured in duplicate using a standardized digital 
scale. Sitting blood pressure was measured in triplicate using an automated oscillometric 
device.   
 
2.4 Safety assessments 
Safety assessments included adverse event (AE) monitoring, BMD and biomarkers of bone 
turnover, physical examination, vital signs (including sitting measurements and postural 
changes in blood pressure and pulse rate) and laboratory evaluations.  
AEs of special interest identified a priori were termed “Tier 1” safety endpoints. These 
included symptomatic hypoglycaemia and AEs associated with genital mycotic infection, 
urinary tract infection (UTI) and hypovolaemia, which were identified according to 
pre-specified sponsor-generated customized MedDRA queries of preferred terms. 
Documented hypoglycaemia, defined as episodes with a glucose level ≤3.9 mmol/L (≤70 
mg/dL) with or without symptoms, was also assessed. Severe hypoglycaemia was defined 
as an episode that required assistance, either medical or non-medical.  
Bone densitometry of lumbar spine (L1–L4), femoral neck, total hip and distal 
forearm regions was measured by dual energy X-ray absorptiometry (DXA) at baseline and 
week 26. DXA scanning procedures were standardized, and all scans were monitored and 
analysed by a central evaluation facility. Blood was collected for analysis of biochemical 
markers of rate of bone turnover (carboxy terminal cross-linking telopeptides of Type I 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
collagen [CTX] and procollagen type 1 N terminal propeptide [P1NP]), parathyroid hormone 
(PTH, secreted in response to low serum calcium) and lipids.  
Changes in renal function were evaluated according to change from baseline in 
eGFR. The number and proportion of participants meeting pre-specified criteria for 
orthostatic change in blood pressure (i.e. supine to standing position) were summarized.11 
 
2.5 Statistical analysis 
The planned sample size of 600 participants (200 per arm) provided >99% power to detect a 
difference of 0.5% between each ertugliflozin dose and placebo in the change from baseline 
at week 26 in HbA1c, assuming a standard deviation (SD) of 1.0% based on a 2-sided test 
at a 5% level of significance. The sample size also provided adequate precision for the 
comparisons of ertugliflozin vs placebo with respect to change in BMD from baseline at week 
26. The half-width of the 95% confidence interval (CI) for the between-treatment difference in 
BMD was expected to be ± 0.7% from the point estimate, which, based on BMD changes of 
~50% of the average change from baseline to week 80 observed for thiazolidinediones, 
would be precise enough to rule out any clinically relevant change.12 Efficacy data obtained 
after initiation of glycaemic rescue therapy were censored (i.e. treated as missing) to avoid 
confounding (termed “excluding glycaemic rescue”). The “excluding glycaemic rescue” 
approach was also the primary analysis for laboratory parameters and AEs (including 
hypoglycaemia), with the exception of serious AEs (SAEs), deaths, AEs resulting in 
discontinuation of study medication, and measurements of postural blood pressure and 
pulse rate, which were assessed using the “including glycaemic rescue” approach.  
 
2.5.1 Analysis of efficacy endpoints 
Efficacy analyses comprised all randomized participants who received ≥1 dose of study 
medication. For endpoints that used a longitudinal data analysis (LDA) model,13 at least one 
measurement (baseline or postbaseline) was required. An ordered testing procedure 
(HbA1c, FPG, body weight, HbA1c <7.0%, SBP, DBP) was used to control the family-wise 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
type 1 error rate at the 0.05 level across all key efficacy endpoints. For each endpoint, the 
15-mg dose was tested vs placebo first, followed by the 5-mg dose vs placebo. Each test 
was performed at the 0.05 level, and testing continued until the first P-value was ≥0.05. 
Change from baseline at week 26 in HbA1c, FPG, body weight, SBP and DBP was 
evaluated using a LDA model that included terms for treatment (categorical), time 
(categorical), the treatment-by-time interaction, menopausal status randomization stratum 
(categorical), AHA status at study entry (binary), and baseline eGFR (continuous) with 
baseline constrained to be the same. No imputation of missing data was performed. A 
logistic regression analysis was used to evaluate the occurrence of HbA1c of <7.0% (53 
mmol/L) at week 26. Missing data at week 26 were imputed via multiple imputation based on 
the primary longitudinal model. Model-based subgroup analyses of the change from baseline 
in HbA1c at week 26 were performed using a repeated measures analysis of covariance 
model. The proportion of participants who received glycaemic rescue therapy in each 
treatment group was compared using the Miettinen and Nurminen method.12,14 
 
2.5.2 Analysis of safety 
The safety analysis set included all participants who received ≥1 dose of study medication. 
For all safety endpoints of a priori interest (“Tier 1” AEs), P-values and 95% CIs (with no 
adjustment for multiplicity) were calculated for between-group comparisons using the 
Miettinen and Nurminen method.14 The term “significantly” higher or lower has been used 
when P < 0.05. Other safety results have been described as “higher” or “lower” as qualitative 
assessment only. The “excluding bone rescue therapy” approach was considered primary for 
BMD, bone biomarker and PTH analyses (however, these data were not censored after 
initiation of glycaemic rescue therapy). Percent changes in BMD endpoints were analysed 
using a LDA model as described for HbA1c.  
Orthostatic changes in SBP and DBP were defined as reductions of ≥20 or ≥10 
mmHg, respectively, after 1 and 3 minutes in the standing position from the supine position 
(relative to the mean value from measurements taken in the supine position). Percent 
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changes from baseline in low- and high-density lipoprotein cholesterol (LDL-C; HDL-C) were 
analysed using the longitudinal method described for HbA1c. Change from baseline in eGFR 
was summarized descriptively.  
 
3 RESULTS 
3.1 Participant disposition and baseline characteristics 
In total, 621 participants were randomized (Figure S1). Demographics and baseline 
characteristics (Table 1) were similar across the treatment groups. The age range was 24 to 
79 years and 15.6% of the study population was aged ≥65 years. Approximately 40% of the 
study population were women who were postmenopausal for ≥3 years. The median 
metformin dose at baseline was 2000 mg/day in all groups. At baseline, 70% of the overall 
population was receiving ≥1 antihypertensive medication; 60%, 22%, 21%, and 24% of 
participants were receiving agents that act on the renin–angiotensin system, beta blockers, 
calcium channel blockers, and diuretics, respectively. The proportion of participants who 
discontinued study medication was 9.1%, 2.9% and 7.3% in the placebo, ertugliflozin 5-mg 
and 15-mg groups, respectively. The most common reason in the placebo and ertugliflozin 
15-mg groups was withdrawal by participant; in the ertugliflozin 5-mg group, the most 
common reasons were withdrawal by participant and AE.  
 
3.2 Efficacy 
Significantly greater reductions in HbA1c at week 26 were observed in both ertugliflozin 
groups compared with the placebo group (P < 0.001 for both comparisons). At week 26, the 
placebo-adjusted least-squares (LS) mean (95% CI) change from baseline in HbA1c was  
–0.7% (–0.9, –0.5) and –0.9% (–1.0, –0.7) for the ertugliflozin 5-mg and 15-mg groups, 
respectively (Table 2; Figures 1A, 1B). Mean (SD) reductions from baseline in HbA1c at 
week 26 were greater in patients with higher baseline HbA1c levels (<8.0%: placebo, 0 [0.9]; 
ertugliflozin 5 mg, –0.4 [0.7]; ertugliflozin 15 mg, –0.5 [0.6]; ≥8.0% to <9.0%: –0.3 [0.9]; –0.7 
[0.9]; –1.1 [0.8], respectively; ≥9.0%: –0.8 [1.0]; –1.7 [1.1]; –1.8 [0.8], respectively). More 
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patients who received ertugliflozin 5 mg (35%) and 15 mg (40%) compared with placebo 
(16%) had HbA1c <7.0% at week 26 (Figure 1C). The model-based odds (95% CI) of HbA1c 
<7.0% relative to placebo were significantly higher in both the ertugliflozin 5-mg (3.0 [1.8, 
5.1]) and 15-mg groups (4.5 [2.6, 7.6]; both P < 0.001). Both ertugliflozin doses also 
provided significantly greater reductions from baseline in FPG (Figure 1D), body weight 
(Figure 1E), SBP (Figure 1F) and DBP (Figure 1G) compared with placebo. By week 26, a 
larger proportion of subjects in the placebo group (17.7%) had received glycaemic rescue 
therapy compared with the ertugliflozin groups (both <3%). 
 
3.3 Safety 
3.3.1 Overall AE summary 
The overall incidence of AEs was similar across groups. The incidence of AEs resulting in 
discontinuation from study medication was low (<2%) and similar across groups. The 
incidence of drug-related AEs was higher in the ertugliflozin groups compared with placebo 
(Table 3), largely owing to AEs related to genital mycotic infections. The incidence of SAEs 
was low and similar across groups, and none were reported as drug related by the 
investigator. There were no cases of ketoacidosis or deaths through week 26. 
 
3.3.2 “Tier 1” AEs/AEs of special interest 
In females, the incidence of genital mycotic infections was higher in the ertugliflozin 5-mg 
group and significantly higher (P < 0.05) in the 15-mg group vs placebo (Table 3). In males, 
the incidence was higher in the ertugliflozin groups vs placebo. Two participants (one each 
in the ertugliflozin 5-mg and 15-mg groups) discontinued study treatment owing to AEs 
related to vulvovaginal complaints. The point estimates for the incidences of UTI and 
symptomatic hypoglycaemia AEs were higher in the ertugliflozin groups vs placebo. One 
participant in the ertugliflozin 15-mg group discontinued study treatment owing to a UTI. The 
incidence of hypovolaemia AEs was similar across groups (Table 3). The incidence of 
documented hypoglycaemia was higher in the ertugliflozin groups (5 mg, 7.2%; 15 mg, 
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7.8%) vs placebo (4.3%). Two participants, one in the ertugliflozin 5-mg group and one in the 
placebo group, experienced an episode of severe hypoglycaemia that required non-medical 
assistance.  
There was no notable change from baseline in the occurrence of events meeting 
orthostatic blood pressure decrease criteria in either ertugliflozin group at weeks 6 (SBP: 5 
mg, 2.0%; 15 mg, 2.1%) or 26 (5 mg, 4.0%; 15 mg, 4.2%), and the incidence was similar to 
placebo (week 6, 3.6%; week 26, 3.7%).  
 
3.3.3 BMD and bone biomarkers 
Ertugliflozin had no adverse impact on BMD at week 26 (Table 4). An assessment by 
subgroup revealed results that were generally similar to those for the overall population (data 
not shown). Three participants, one in each group, had adjudication-confirmed fractures. 
One participant (in the ertugliflozin 5-mg group) met bone rescue criteria and received 
treatment. Mean serum CTX at week 26 was increased in the ertugliflozin groups in a dose-
related manner, but mean P1NP and PTH levels at week 26 were similar to baseline (Table 
S1).  
 
3.3.4 Laboratory parameters 
Small mean increases from baseline in magnesium and phosphate were initially observed at 
week 6 and were maintained through week 26 in both ertugliflozin groups. There was no 
notable change from baseline in serum calcium (Table S2).  
In the ertugliflozin groups, decreases from baseline in eGFR (see Table 1), initially 
observed at week 6 (3.2 and 3.3 mL/min/1.73 m2 in the 5-mg and 15-mg groups, 
respectively), returned to baseline values at week 26. There was no notable change from 
baseline in the placebo group. The proportion of participants with a >30% decrease in eGFR 
was low but was higher in ertugliflozin groups (2.0% in both) compared with placebo (0.5%). 
One participant (0.5%) in the ertugliflozin 15-mg group had a >50% decrease from baseline 
in eGFR.  
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At week 26, the LS mean (95% CI) placebo-adjusted percent change from baseline 
in LDL-C was 2.0% (–6.0, 10.0) in the ertugliflozin 5-mg group and 2.6% (–5.5, 10.7) in the 
15-mg group. Baseline values were: placebo, 99.3 mg/dL; ertugliflozin 5 mg, 98.8 mg/dL; 
ertugliflozin 15 mg, 93.2 mg/dL. Corresponding placebo-adjusted percent changes for HDL-
C were: ertugliflozin 5 mg, 4.5% (1.4, 7.6); ertugliflozin 15 mg, 4.4% (1.3, 7.5). Baseline 
values were: placebo, 48.6 mg/dL; ertugliflozin 5 mg, 48.5 mg/dL; ertugliflozin 15 mg, 48.2 
mg/dL. 
 
4 DISCUSSION 
In this study, the addition of ertugliflozin at doses of 5 mg and 15 mg once daily to metformin 
monotherapy over 26 weeks improved glycaemic control and reduced body weight, SBP and 
DBP without impacting BMD, but it increased the incidence of genital mycotic infections. 
With both doses of ertugliflozin, decreases in HbA1c were clinically relevant and 
consistent with reports for other SGLT2 inhibitors.1,2,15 Treatment with ertugliflozin also 
resulted in significant improvements relative to placebo in other glycaemic measures, 
including FPG, and in the proportion of participants with HbA1c <7%. In addition, treatment 
with ertugliflozin resulted in significantly greater reductions in body weight, SBP and DBP at 
week 26 relative to placebo. Although this trial was not designed to formally compare the two 
ertugliflozin doses tested, the 15-mg dose appeared to be associated with slightly greater 
reductions in the primary and key secondary endpoints, except for body weight loss, which 
was similar between the two doses. 
The incidence of genital mycotic infections was more frequent in ertugliflozin groups 
vs placebo. This is a known class effect of SGLT2 inhibitors, and these findings are 
consistent with the increased relative risk for genital mycotic infections reported in a meta-
analysis of SGLT2 inhibitors.16 Consistent with reports for dapagliflozin17 and canagliflozin,18 
in the current study there was a trend for a higher incidence of UTI AEs in ertugliflozin 
groups vs placebo, but there were no cases of complicated UTIs. Symptomatic 
hypoglycaemia and documented hypoglycaemic events were infrequent. 
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Bone safety remains an area of interest for SGLT2 inhibitors. The strongest evidence 
for bone safety involves assessment of fracture risk. However, assessment of BMD and 
bone biomarkers can also be informative. Potentially disparate effects on fracture are noted 
for SGLT2 inhibitors based on indirect comparisons of phase III results. In the canagliflozin 
program, an increase in fractures was noted as early as 12 weeks.19 While no imbalance of 
fractures was evident in the dapagliflozin program, increased incidence was observed in a 
study of individuals with moderate renal impairment.20 The incidence of bone fractures in 
patients treated with empagliflozin was low and similar to placebo,21 and was confirmed by 
pooled analysis.22 
In a study in patients aged 55–80 years, at 2 years, individuals randomized to 
canagliflozin 100 or 300 mg had placebo-adjusted declines in BMD at the total hip of 0.9% 
and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively.23,24 In the 
same study, at week 26, canagliflozin was associated with increases in CTX, a biomarker of 
bone resorption, of 16.2% and 23.9%, respectively, and decreases in P1NP, a biomarker of 
bone formation, of 5.5% and 6.8%, respectively.25 No meaningful changes from baseline in 
markers of bone turnover or BMD in patients who received dapagliflozin added to metformin 
were reported after either 5026 or 102 weeks.27 However, the dapagliflozin study was small 
(n=182) and did not have a population enriched with older participants. 
Through 26 weeks, ertugliflozin had no adverse impact on BMD in either the overall 
population or the cohort of women postmenopausal for ≥3 years. The study protocol also 
includes BMD assessment at weeks 52 and 104; these data, along with future pooled 
analyses of fracture risk in the phase III program, will inform on bone safety outcomes 
associated with longer-term treatment with ertugliflozin. Participants in ertugliflozin groups 
had increased serum CTX compared with those in the placebo group. Levels of P1NP and 
PTH did not differ between groups through 26 weeks. The clinical relevance of these 
laboratory findings, coupled with the lack of change in BMD at week 26 in particular, is 
unclear. Longer-term data on bone biomarkers and PTH will be available when the 78-week 
extension phase is completed. 
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Small increases in HDL-C and LDL-C were noted with ertugliflozin, consistent with 
reports of other SGLT2 inhibitors.28 SGLT2 inhibitors have also been associated with 
transient increases in serum creatinine and decreases in eGFR.29 In this study, there was an 
initial decrease in eGFR at week 6 in ertugliflozin groups (without dose effect), but by week 
26 values had returned to baseline and were similar to placebo.  
 
5 CONCLUSIONS 
In participants with T2DM who had inadequate glycaemic control on metformin 
monotherapy, the addition of ertugliflozin for 26 weeks provided meaningful improvements in 
glycaemic control and significant reductions in body weight, SBP and DBP. Ertugliflozin was 
generally well tolerated; however, it was associated with a higher incidence of genital 
mycotic infections compared with placebo. 
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FIGURE LEGENDS 
 
FIGURE 1 Efficacy outcomes: (A) LS mean (± SE) change from baseline in HbA1c at 
week 26; (B) LS mean (95% CI) change from baseline in HbA1c at week 26; (C) proportion 
of participants with HbA1c <7% at week 26. LS mean change from baseline at week 26 in 
(D) FPG; (E) body weight; (F) SBP; and (G) DBP. 
 
FIGURE S1 Participant disposition. 
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TABLE 1 Baseline demographics and treatment characteristics 
 Placebo 
(N=209) 
Ertugliflozin 5 mg 
(N=207) 
Ertugliflozin 15 mg 
(N=205) 
Total 
(N=621) 
Male, n (%)                                         
Age, years ± SD                                       
Duration of T2DM, years ± SD 
98 (46.9) 
56.5 ± 8.7 
8.0 ± 6.3 
97 (46.9) 
56.6 ± 8.1 
7.9 ± 6.1 
93 (45.4) 
56.9 ± 9.4 
8.1 ± 5.5 
288 (46.4) 
56.6 ± 8.8 
8.0 ± 6.0 
Background AHA therapy at screening, n (%)1 
Metformin 
DPP-4 inhibitors 
Other blood glucose lowering agents  
Sulphonamides, urea derivatives  
Number of agents  
1 
2  
209 (100.0) 
7 (3.3) 
0 (0) 
62 (29.7) 
 
140 (67.0) 
69 (33.0) 
207 (100.0) 
6 (2.9) 
3 (1.4) 
57 (27.5) 
 
141 (68.1) 
66 (31.9) 
204 (99.5)2 
8 (3.9) 
2 (1.0) 
45 (22.0) 
 
151 (73.7) 
54 (26.3) 
620 (99.8) 
21 (3.4) 
5 (0.8) 
164 (26.4) 
 
432 (69.6) 
189 (30.4) 
Race, n (%) 
Asian                                                      
Black or African American                                  
Multiple                                                   
White                                                      
31 (14.8) 
19 (9.1) 
15 (7.2) 
144 (68.9) 
34 (16.4) 
22 (10.6) 
17 (8.2) 
134 (64.7) 
35 (17.1) 
23 (11.2) 
14 (6.8) 
133 (64.9) 
100 (16.1) 
64 (10.3) 
46 (7.4) 
411 (66.2) 
Region, n (%) 
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 Placebo 
(N=209) 
Ertugliflozin 5 mg 
(N=207) 
Ertugliflozin 15 mg 
(N=205) 
Total 
(N=621) 
North America                 
South America        
Europe                                  
Asia                                                       
South Africa  
Australia/New Zealand                                           
55 (26.3) 
9 (4.3) 
76 (36.4) 
26 (12.4) 
39 (18.7) 
4 (1.9) 
61 (29.5) 
4 (1.9) 
74 (35.7) 
27 (13.0) 
35 (16.9) 
6 (2.9) 
53 (25.9) 
8 (3.9) 
74 (36.1) 
32 (15.6) 
37 (18.0) 
1 (0.5) 
169 (27.2) 
21 (3.4) 
224 (36.1) 
85 (13.7) 
111 (17.9) 
11 (1.8) 
Body weight, kg 84.5 ± 17.1 84.8 ± 17.2 85.3 ± 16.5 84.9 ± 16.9 
BMI, kg/m2 30.7 ± 4.7 30.8 ± 4.8 31.1 ± 4.5 30.9 ± 4.7 
HbA1c, % 8.2 ± 0.9 8.1 ± 0.9 8.1 ± 0.9 8.1 ± 0.9 
FPG, mmol/L 9.4 ± 2.3 9.3 ± 2.5 9.3 ± 2.5 9.3 ± 2.4 
eGFR3, mL/min/1.73 m2 91.6 ± 19.8 88.9 ± 17.5 91.0 ± 20.6 90.5 ± 19.3 
Stratification factor: menopausal status  
Men 
Women 
Pre-menopausal  
Perimenopausal or <3 years postmenopausal  
≥3 years postmenopausal  
97 (46.4) 
 
16 (7.7) 
9 (4.3) 
87 (41.6) 
97 (46.9) 
 
17 (8.2) 
10 (4.8) 
83 (40.1) 
93 (45.4) 
 
16 (7.8) 
11 (5.4) 
85 (41.5) 
287 (46.2) 
 
49 (7.9) 
30 (4.8) 
255 (41.1) 
Data are mean ± SD or n (%) where indicated.  
Abbreviations: AHA, anti-hyperglycaemic agent; BMI, body mass index; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; FPG, 
fasting plasma glucose; HbA1c, glycated haemoglobin; SD, standard deviation; T2DM, type 2 diabetes mellitus. 
1 Combination blood glucose lowering agents are counted twice, under each component of the combination. 
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 Placebo 
(N=209) 
Ertugliflozin 5 mg 
(N=207) 
Ertugliflozin 15 mg 
(N=205) 
Total 
(N=621) 
2 One patient was not on metformin at the first screening visit but started at the second screening visit. 
3 n numbers for eGFR were: placebo, 202; ertugliflozin 5 mg, 199; ertugliflozin 15 mg, 201; total, 602. 
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TABLE 2 Change from baseline in HbA1c (%) at week 26 
Treatment 
Baseline Week 26 Change from baseline at week 26 
N Mean (SD) N Mean (SD) N Mean (SD) LS mean (95% CI)1 
Placebo 
Ertugliflozin 5 mg 
Ertugliflozin 15 mg 
207 
205 
201 
8.2 (0.9)  
8.1 (0.9)  
8.1 (0.9) 
151 
191 
186 
7.8 (1.1)  
7.3 (0.8)  
7.2 (0.8)  
209 
207 
205 
–0.2 (0.9)  
–0.7 (0.9)  
–1.0 (0.9)  
0.0 (–0.2, 0.1)  
–0.7 (–0.8, –0.6)  
–0.9 (–1.0, –0.8) 
Pairwise comparison Difference in LS means (95% CI)1 P-value1 
Week 26 ertugliflozin 5 mg vs placebo 
Week 26 ertugliflozin 15 mg vs placebo 
–0.7 (–0.9, –0.5)  
–0.9 (–1.0, –0.7)  
<0.001  
<0.001  
Based on the full analysis set, excluding data after initiation of glycaemic rescue therapy.  
Abbreviations: AHA, anti-hyperglycaemic agent; CI, confidence interval; cLDA, constrained longitudinal data analysis; eGFR, estimated glomerular 
filtration rate; HbA1c, glycated haemoglobin; LS, least-squares; SD, standard deviation. 
1 Based on cLDA model with fixed effects for treatment, time, prior AHA (metformin monotherapy or metformin + another AHA), baseline eGFR 
(continuous), menopausal status randomization stratum (men, pre-menopausal women, women perimenopausal or <3 years postmenopausal, 
women ≥3 years postmenopausal) and the treatment-by-time interaction. Time was treated as a categorical variable. 
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TABLE 3 Summary of overall safety and selected AEs 
n (%)1 
Placebo 
(N=209) 
Ertugliflozin  
5 mg 
(N=207) 
Ertugliflozin 
15 mg 
(N=205) 
Overall safety 
One or more AEs 
AEs related to study drug 
One or more SAEs 
SAE related to study drug 
Death 
AE leading to discontinuation of 
study medication 
94 (45.0) 
13 (6.2) 
8 (3.8) 
0 (0) 
0 (0) 
3 (1.4) 
88 (42.5) 
24 (11.6) 
3 (1.4) 
0 (0) 
0 (0) 
3 (1.4) 
103 (50.2) 
25 (12.2) 
7 (3.4) 
0 (0) 
0 (0) 
3 (1.5) 
Tier 1 AEs 
Genital mycotic infection (women) 
Genital mycotic infection (men) 
UTI 
Symptomatic hypoglycaemia 
Hypovolaemia 
1 (0.9) 
0 (0) 
2 (1.0) 
4 (1.9) 
1 (0.5) 
6 (5.5) 
3 (3.1) 
6 (2.9) 
7 (3.4) 
1 (0.5) 
7 (6.3)2 
3 (3.2) 
7 (3.4) 
7 (3.4) 
2 (1.0) 
Other selected AEs    
Documented hypoglycaemia3 
Pollakiuria  
Dizziness  
9 (4.3) 
0 (0)  
1 (0.5) 
15 (7.2) 
3 (1.4) 
3 (1.4) 
16 (7.8) 
3 (1.5) 
1 (0.5) 
Data are shown as n (%).  
Abbreviations: AE, adverse event; SAE, serious adverse event; UTI, urinary tract infection. 
1 The “including rescue” approach (analysis including data obtained after the initiation of glycaemic 
rescue therapy) was the primary analysis for SAEs, deaths and discontinuations due to AEs. The 
“excluding rescue” approach (analysis excluding events occurring after glycaemic rescue 
medication) was the primary analysis for all other endpoints. 
2 Incidence significantly higher (P = 0.032) vs placebo group.   
3 Episodes with a glucose level ≤3.9 mmol/L (70 mg/dL) with or without symptoms. 
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TABLE 4 Percent change from baseline to week 26 in BMD measured by DXA 
Treatment 
Baseline Week 26 Change (%) from baseline at week 26 
Change (%) from baseline  
vs placebo 
N Mean (SD) N Mean (SD) N Mean (SD) LS mean (95% CI)1 
Difference in LS means (95% 
CI)1 
Lumbar spine 
Placebo 
Ertugliflozin 5 mg 
Ertugliflozin 15 mg 
209 
207 
204 
1.15 (0.181) 
1.13 (0.184) 
1.10 (0.168) 
191 
200 
190 
1.15 (0.184) 
1.13 (0.188) 
1.11 (0.169) 
191 
200 
189 
0.20 (2.919)  
0.00 (3.191)  
0.15 (2.884)  
0.22 (–0.20, 0.65)  
–0.01 (–0.42, 0.41)  
0.12 (–0.31, 0.55)  
– 
–0.23 (–0.83, 0.37) 
–0.10 (–0.71, 0.50) 
Femoral neck 
Placebo 
Ertugliflozin 5 mg 
Ertugliflozin 15 mg 
209 
207 
205 
0.92 (0.167) 
0.92 (0.162) 
0.89 (0.153) 
191 
200 
190 
0.92 (0.166) 
0.92 (0.165) 
0.89 (0.152) 
191 
200 
190 
–0.42 (3.296)  
–0.10 (3.237)  
0.33 (3.797)  
–0.40 (–0.89, 0.09)  
–0.10 (–0.57, 0.38)  
0.30 (–0.19, 0.79)  
– 
0.30 (–0.38, 0.99) 
0.70 (0.00, 1.39) 
Total hip 
Placebo 
Ertugliflozin 5 mg 
Ertugliflozin 15 mg 
209 
207
205 
1.06 (0.154)
1.07 (0.150)
1.04 (0.138)
191 
200 
190 
1.06 (0.156)
1.06 (0.155)
1.04 (0.138)
191 
200 
190 
–0.62 (1.963) 
–0.54 (2.013) 
–0.36 (2.177) 
–0.63 (–0.92, –0.34) 
–0.55 (–0.83, –0.27) 
–0.36 (–0.65, –0.07) 
– 
0.08 (–0.33, 0.48) 
0.27 (–0.15, 0.68) 
Distal forearm 
Placebo 
Ertugliflozin 5 mg 
Ertugliflozin 15 mg 
209 
204 
205 
0.81 (0.136) 
0.81 (0.137) 
0.79 (0.134) 
191 
200 
189 
0.81 (0.133) 
0.81 (0.138) 
0.80 (0.134) 
190 
197 
189 
0.07 (3.049)  
–0.14 (2.692)  
–0.08 (2.826)  
0.06 (–0.35, 0.47)  
–0.15 (–0.55, 0.24)  
–0.13 (–0.53, 0.28) 
– 
–0.21 (–0.78, 0.35)  
–0.19 (–0.76, 0.39) 
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Data are excluding bone rescue approach.  
Abbreviations: AHA, anti-hyperglycaemic agent; BMD, bone mineral density; CI, confidence interval; cLDA, constrained longitudinal data analysis; DXA, dual 
energy X-ray absorptiometry; eGFR, estimated glomerular filtration rate; LS, least-squares; SD, standard deviation. 
1 Based on cLDA model with fixed effects for treatment, time, prior anti-hyperglycaemic medication (metformin monotherapy or metformin + another AHA), 
baseline eGFR (continuous), menopausal status randomization stratum (men, pre-menopausal women, women perimenopausal or <3 years postmenopausal, 
women ≥3 years postmenopausal) and the treatment-by-time interaction. Time was treated as a categorical variable.
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[FIGURE 1] 
 
*P < 0.001 vs placebo; **P = 0.002 vs placebo; †P = 0.013; ††P = 0.001. Excluding data after initiation 
of glycaemic rescue therapy. CI, confidence interval; DBP, diastolic blood pressure; FPG, fasting 
plasma glucose; HbA1c, glycated haemoglobin; LS, least-squares; PBO, placebo; SBP, systolic blood 
pressure; SE, standard error. 
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